A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Trial information

Medical condition

ALL

Trial phase

Phase 2/3

Sponsor

Merch Sharp & Dohme

Start date

31/07/2026

Main objective

To compare the efficacy and safety of MK-1045 versus blinatumomab in participants with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (B-ALL), with primary endpoints likely including complete remission rate and/or overall survival.

Locations and Contact points